Editas Medicine Reveals Updated Safety And Efficacy Results From The RUBY Trial Of Reni-Cel In 18 Sickle Cell Patients At EHA
Editas Medicine Reveals Updated Safety And Efficacy Results From The RUBY Trial Of Reni-Cel In 18 Sickle Cell Patients At EHA
editas medicine披露了RUBY試驗中Reni-Cel在18例鐮狀細胞病患者中的安全性和有效性更新結果，此次試驗由歐洲血液學會主辦。
- All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion
- Patients had early normalization of total hemoglobin with a mean within the normal range at >14 g/dL and rapid and sustained improvements in fetal hemoglobin well above levels of >40%.
- Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant
- 所有接受RUBY試驗治療的患者，在接受renizgamglogene autogedtemcel（reni-cel）輸注後均未發生血管閉塞事件。
- 患者的總血紅蛋白早期恢復，平均達到正常範圍大於14 g/dL，並且胎兒血紅蛋白水平迅速持續上升，遠高於40%的水平。
- Reni-cel耐受性良好，並呈現出與用巴磺酸進行髓毒性調節和自體造血幹細胞移植相一致的安全性。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。